This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys

New York City-based Findell Capital Management disclosed a new $9.5 million position in Mineralys Therapeutics (NASDAQ:MLYS) as of its November 14 SEC filing.According to a filing with the Securities and Exchange Commission dated November 14, Findell Capital Management initiated a new position in Mineralys Therapeutics (NASDAQ:MLYS), acquiring 250,000 shares in the third quarter. The stake was valued at $9.5 million, representing 3.7% of the fund’s $253.4 million U.S. equity portfolio as of September 30. The fund reported 15 positions in total.Top holdings after the filing:  Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool